<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="33265">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02673606</url>
  </required_header>
  <id_info>
    <org_study_id>2007P000496</org_study_id>
    <nct_id>NCT02673606</nct_id>
  </id_info>
  <brief_title>Impact of Estrogen on Fear Extinction</brief_title>
  <official_title>The Influence of Estrogen on the Fear Extinction Network in Humans</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Massachusetts General Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Massachusetts General Hospital</source>
  <brief_summary>
    <textblock>
      The goal of this project is to examine how estrogen may influence the resting-state
      connectivity and the extinction-induced activation of the fear extinction network.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>January 2013</start_date>
  <primary_completion_date type="Anticipated">January 2017</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Double Blind (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Blood-oxygen-level dependent (BOLD) signal during extinction recall as a function of group assignment (placebo, 2mg estradiol, 4mg estradiol)</measure>
    <time_frame>These measures will be collected Day 3.</time_frame>
    <description>BOLD signal in the regions of the fear extinction network will be measured to assess between-group differences during extinction recall.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Skin conductance responses during extinction extinction recall as a function of group assignment (placebo, 2mg estradiol, 4mg estradiol)</measure>
    <time_frame>These measures will be collected on Day 3.</time_frame>
    <description>Skin conductance responses are a psychophysiological index of fear levels. Levels yielded during extinction recall will be compared across the 3 groups to examine the impact of estradiol administration.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood-oxygen-level dependent (BOLD) signal during extinction learning as a function of group assignment (placebo, 2mg estradiol, 4mg estradiol)</measure>
    <time_frame>These measures will be collected on Day 2.</time_frame>
    <description>BOLD signal in the regions of the fear extinction network will be measured during extinction learning to assess between-group differences.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Skin conductance responses during extinction learning as a function of group assignment (placebo, 2mg estradiol, 4mg estradiol)</measure>
    <time_frame>These measures will be collected on Day 2.</time_frame>
    <description>Skin conductance responses will be compared across the 3 groups to examine the impact of estradiol administration on extinction learning.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">150</enrollment>
  <condition>Healthy Naturally Cycling Women</condition>
  <arm_group>
    <arm_group_label>Estradiol 2mg Dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>2mg dose of estradiol (oral administration)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Estradiol 4mg Dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>4mg dose of estradiol (oral administration)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>placebo (oral administration)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Estradiol</intervention_name>
    <arm_group_label>Estradiol 2mg Dose</arm_group_label>
    <arm_group_label>Estradiol 4mg Dose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Right-handed

          -  Naturally-cycling (regular cycle)

          -  No current or past history of Axis I psychiatric disorders

        Exclusion Criteria:

          -  Psychiatric, neurologic or medical condition that would interfere with study
             procedures or confound results, ascertained by history.

          -  History of seizure or significant head trauma (i.e., extended loss of consciousness,
             neurological sequelae, or known structural brain lesion).

          -  History of Axis I psychiatric diagnosis; e.g., history of substance use disorder,
             psychotic disorder, bipolar disorder, tic disorder, or eating disorder.

          -  Use of psychotropic medication within 4 weeks prior to study (within 6 weeks for
             fluoxetine, or other long-lived compounds; within one year for neuroleptics).

          -  Pregnancy (to be ruled out by urine ÃŸ-HCG).

          -  Metallic implants or devices contraindicating magnetic resonance imaging.

          -  Use of oral contraceptives or non-oral contraceptives containing estrogen and
             progesterone within 3 months

          -  History of breast cancer.

          -  Allergy to peanut oil.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>30 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mohammed Milad, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Massachusetts General Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Marie-France Marin, PhD</last_name>
    <phone>617-724-1729</phone>
    <email>marie-france.marin@mgh.harvard.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Massachusetts General Hospital (149 13th Street - Charlestown Navy Yard)</name>
      <address>
        <city>Charlestown</city>
        <state>Massachusetts</state>
        <zip>02129</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marie-France Marin, PhD</last_name>
      <phone>617-724-1729</phone>
      <email>marie-france.marin@mgh.harvard.edu</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2016</verification_date>
  <lastchanged_date>February 1, 2016</lastchanged_date>
  <firstreceived_date>January 26, 2016</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Massachusetts General Hospital</investigator_affiliation>
    <investigator_full_name>Mohammed R Milad</investigator_full_name>
    <investigator_title>Associate Professor</investigator_title>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Estradiol</mesh_term>
    <mesh_term>Polyestradiol phosphate</mesh_term>
    <mesh_term>Estrogens</mesh_term>
    <mesh_term>Estradiol 3-benzoate</mesh_term>
    <mesh_term>Estradiol 17 beta-cypionate</mesh_term>
    <mesh_term>Estradiol valerate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
